Home Health Care Sizzling News: Pulmatrix Inc (NASDAQ:PULM)

Sizzling News: Pulmatrix Inc (NASDAQ:PULM)

1
0
SHARE

Shares of Pulmatrix Inc (NASDAQ:PULM) ended Monday session in green amid volatile trading. The shares closed up +0.010 points or 1.43% at $0.710 with 26,024 shares getting traded. Post opening the session at $0.72, the shares hit an intraday low of $0.68 and an intraday high of $0.78 and the price vacillated in this range throughout the day.

Market Cap/Outstanding Shares

The company has a market cap of $9.52 million and the number of outstanding shares have been calculated to be 14.70 million shares.

Performance weekly/monthly/quarterly/yearly in percentage (%)

The performance for the week is valued at -8.39%, resulting in a performance for the month at -50.35%. Therefore, the stated figure displays a quarterly performance of -57.99% and an annual performance of -85.94% traded up 1.43% on 28 November, 2016 hitting $0.710.

P/S-P/B-P/C

Pulmatrix Inc has a P/S value of 6.53, measuring P/B at 0.60. Its P/Cash is valued at 1.43.

ATR/Volatility

Avg. true range is 0.12. Historically, the volatility of this stock is about 12.21% a week and 15.07% a month.

Pulmatrix Inc (PULM) recently declared it third quarter financial results and business update.

Revenues for the third quarter of 2016 were $0.1 million, contrast to $0.7 million for the third quarter of 2015. The decrease was the result of the reduced revenue associated with the conclusion of the clinical study funded under our partnershipagreement with Mylan to develop PUR0200 for COPD.

Research and development expenses for the third quarter of 2016 were $1.5 million, contrast to $2.2 million for the same period last year. The decrease was mainly because of decreases in clinical development costs and external service costs on the PUR1900 project. General and administrative expenses for the third quarter of 2016 were $1.6 million, contrast to $3.1 million for the same period in 2015. The decrease was mainly because of a reduction in employee stock-based compensation expense and non-recurring merger related expenses that were incurred during the third quarter of 2015.

Net loss for the third quarter of 2016 was $3.2 million contrast to a net loss of $4.9 million in the same period last year. The decrease in net loss is attributable to the noted operating expense decreases.

As of September 30, 2016, Pulmatrix had $7.3 million in cash and cash equivalents, contrast to $18.9 million as of December 31, 2015.